These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9639387)

  • 1. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
    van Gog FB; Brakenhoff RH; Stigter-van Walsum M; Snow GB; van Dongen GA
    Int J Cancer; 1998 Jul; 77(1):13-8. PubMed ID: 9639387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
    Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
    van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
    Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
    Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
    Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled monoclonal antibody E48.
    Gerretsen M; Visser GW; Brakenhoff RH; van Walsum M; Snow GB; van Dongen GA
    Cell Biophys; 1994; 24-25():135-42. PubMed ID: 7736517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
    Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
    Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
    Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR.
    Laytragoon-Lewin N; Ustun H; Castro J; Friesland S; Ghaderi M; Lundgren J; Turesson I; Lewin F
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):203-9. PubMed ID: 18758819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience.
    Colnot DR; Quak JJ; Roos JC; de Bree R; Wilhelm AJ; Snow GB; van Dongen GA
    Head Neck; 2001 Jul; 23(7):559-65. PubMed ID: 11400244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
    Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
    Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
    J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental radioimmunotherapy of a xenografted human glioma using 131I-labeled monoclonal antibody to epidermal growth factor receptor.
    Takahashi H; Nakazawa S; Herlyn D
    Neurol Med Chir (Tokyo); 1993 Sep; 33(9):610-5. PubMed ID: 7505399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
    de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
    Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.
    Verel I; Heider KH; Siegmund M; Ostermann E; Patzelt E; Sproll M; Snow GB; Adolf GR; van Dongen GA
    Int J Cancer; 2002 May; 99(3):396-402. PubMed ID: 11992408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.